Baxalta Manufacturing Sarl – FDA 483
An FDA inspection of Baxter Bioscience Manufacturing Sarl in Neuchatel, Switzerland, revealed significant deficiencies in quality control and manufacturing processes for its Advate lyophilized final drug product. The firm released multiple lots of product affected by unexplained discoloration without completing investigations or assessing patient safety. Additionally, the inspection found inadequate complaint investigations, insufficient release and stability testing, and procedures that failed to ensure product quality after out-of-specification results or unknown residues in equipment.
- Company
- Baxalta Manufacturing Sarl
- Product type
- biologics
ID · 7dabb44a-9d7b-4e72-888e-05bd1780254c
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.